Asset Details
Do you wish to reserve the book?
Monitoring of the Anticoagulants Argatroban and Lepirudin
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Monitoring of the Anticoagulants Argatroban and Lepirudin
Do you wish to request the book?
Monitoring of the Anticoagulants Argatroban and Lepirudin
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Monitoring of the Anticoagulants Argatroban and Lepirudin
2011
Overview
Monitoring of direct inhibitors of thrombin (DTI) is critical for their safe and effective use as anticoagulants. We examined samples containing several concentrations of argatroban or lepirudin in reconstituted standard human plasma and plasma from medical outpatients and intensive care patients. Prothrombin time (PT), activated partial thromboplastin time (aPTT), and thrombin time (TT) were determined using automated analyzers. Ecarin clotting time (ECT) was measured using a 10 IU/mL dilution of ecarin in 0.05 mol/L CaCl2. Calibration curves were approximately linear for TT and ECT in samples containing argatroban and lepirudin, respectively. Activated partial thromboplastin curves reached a plateau at DTI concentrations ≥2 µg/mL, suggesting that the aPTT may not reliably detect overdosing. Prothrombin time increased exponentially. A broad range of clotting times was seen in patient samples with all tests suggesting that individual morbidity and therapies may strongly influence test results and may lead to underestimation of DTI doses.
Publisher
SAGE Publications
Subject
Antithrombins - administration & dosage
/ Antithrombins - pharmacokinetics
/ Female
/ Hirudins - administration & dosage
/ Humans
/ Male
/ Partial Thromboplastin Time - methods
/ Partial Thromboplastin Time - standards
/ Pipecolic Acids - administration & dosage
/ Pipecolic Acids - pharmacokinetics
/ Prothrombin Time - standards
/ Recombinant Proteins - administration & dosage
We currently cannot retrieve any items related to this title. Kindly check back at a later time.